We were fortunate to meet with MDS Congress Scientific Program Committee member, Antonio Strafella (Toronto Western Hospital, University Health Network, University of Toronto, Ontario, Canada) who spoke to us about imaging biomarkers of cognitive decline in Parkinson’s disease.
1. What is known about the pathological processes underlying cognitive decline in Parkinson’s disease (PD)? (0:05)
2. What neuroimaging biomarkers appear useful in this setting? (1:40)
3. What are the most promising CSF biomarkers of cognitive decline in PD? (3:18)
4. What genetic factors affect the risk of cognitive decline in patients with PD? (4:17)
5. What further research is needed before these biomarkers enter clinical use? (5:44)
Speaker disclosure: Antonio P Strafella has received funding from the Canada Research Chairs Program (CRCP), Canadian Institutes of Health Research (CIHR), National Parkinson Foundation (NPF), Parkinson Disease Foundation (PDF), Parkinson Canada, Ontario Gambling Association, Tourette Syndrome Association (TSA), Brain Canada, Weston Brain Institute, and honoraria from GE Healthcare Canada Ltd.
Filmed at the International Congress of Parkinson’s Disease and Movement Disorders (MDS), Nice, France, September 2019.
Share this Video
Related Videos In Parkinson's Disease
Heinz Reichmann, EAN 2021: OPTIPARK Study Findings
We were delighted to meet with Heinz Reichmann (Technische Universität Dresden, Dresden, Germany) to discuss the key real world findings from the OPTIPARK study, investigating the use of Opicapone in the treatment of Parkinson’s disease. The abstract entitled: ‘Opicapone in Parkinson’s patients with motor fluctuations and complications of therapy at baseline: the OPTIPARK study’ was presented […]
Heinz Reichmann, EAN 2021: Levodopa-based Drugs in the Treatment of Parkinson’s Disease
We were delighted to meet with Heinz Reichmann (Technische Universität Dresden, Dresden, Germany) to discuss the use of levodopa-based drugs for managing Parkinson’s disease. The abstract entitled: ‘Opicapone in Parkinson’s patients with motor fluctuations and complications of therapy at baseline: the OPTIPARK study’ was presented at the 7th Congress of the European Academy of Neurology […]
Stephen Pasternak, AD/PD 2021: Phase 2 trial Investigating Ambroxol as a Treatment for Parkinson’s Disease Dementia
It was a great pleasure to speak with Stephen Pasternak (University of Western Ontario, Ontario, Canada) to discuss the phase 2 trial investigating ambroxol as a disease-modifying treatment for Parkinson’s Disease dementia. The abstract entitled ‘Ambroxol as a Disease-modifying Treatment for Parkinson’s Disease Dementia: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial’ was presented at The […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!